iifl-logo

Sun Pharmaceuticals Industries Ltd Historical Data

1,687.4
(-0.19%)
Jun 12, 2025|03:59:56 PM

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Sun Pharmaceuticals Industries Ltd Historical Data

12/05/2025calendar-icon
12/06/2025calendar-icon
Date
Open(₹)
High(₹)
Low(₹)
Close(₹)
No. Of Trades(₹)
Total Turnover(₹)
Deliverable Quantity(₹)

13-May-2025

1,711

1,748.51,691.31,7002,58,13511,92,53,08,73540,32,920

14-May-2025

1,702

1,711.41,692.11,708.282,2742,79,24,49,090.110,30,277

15-May-2025

1,701.1

1,744.41,684.11,740.11,46,8906,67,62,83,657.420,99,534

16-May-2025

1,740

1,741.61,7191,734.992,5932,50,85,37,705.67,85,798

19-May-2025

1,745

1,7651,726.61,730.21,05,2303,61,08,45,209.612,74,712

20-May-2025

1,743.8

1,7481,703.31,707.81,13,0194,64,52,60,502.919,33,363

21-May-2025

1,716.4

1,758.71,707.81,731.884,6404,78,59,60,056.213,07,555

22-May-2025

1,734.2

1,7401,707.21,718.788,3894,58,66,18,23014,86,439

23-May-2025

1,658

1,689.51,636.61,683.64,09,88013,91,59,33,663.154,45,069

26-May-2025

1,693.1

1,702.41,6671,676.11,94,7133,82,60,44,956.413,52,771

27-May-2025

1,676.1

1,6921,661.11,683.41,34,3844,70,45,03,192.116,22,707

28-May-2025

1,683.4

1,686.91,6631,666.490,6294,44,76,03,093.818,55,752

29-May-2025

1,675

1,703.31,670.41,699.81,26,1014,01,96,78,075.314,59,692

30-May-2025

1,702

1,713.61,669.11,677.691,3986,13,10,78,417.326,11,830

02-Jun-2025

1,679

1,683.51,660.51,674.696,5653,04,55,87,489.213,04,180

03-Jun-2025

1,695

1,6951,657.61,667.51,10,8384,26,49,41,89515,41,709

04-Jun-2025

1,656

1,6691,6491,664.964,4332,82,58,80,489.210,20,975

05-Jun-2025

1,662

1,694.31,6621,683.197,2173,42,38,04,103.712,03,563

06-Jun-2025

1,685

1,6891,6691,679.298,4714,19,12,08,633.518,52,030

09-Jun-2025

1,679.9

1,698.81,673.31,694.462,2704,35,58,55,57319,79,519

10-Jun-2025

1,701.8

1,706.91,677.71,688.873,6203,99,78,60,997.714,95,109

11-Jun-2025

1,694.8

1,6951,679.31,690.667,4403,37,49,55,992.713,33,427

Sun Pharma.Inds.: Related NEWS

Sun Pharma Expands Specialty Drug Pipeline with $25 Million Pharmazz Deal
24 May 2025|07:51 PM

Both treatments have already received approvals in India and are available for sale there with local partners under a brand known as Tyvalzi and Lyfaquin.

Read More
Sun Pharma Q4 FY25 Revenue Rises 8.5% to ₹12,816 Crore
23 May 2025|12:07 PM

The Board recommended a final dividend of ₹5.50 per share for FY25.

Read More
Top Stocks for Today - 7th May 2025
7 May 2025|08:06 AM

NLC's subsidiary has executed a PPA with Rajasthan Rajya Vidyut Utpadan Nigam Ltd. (RVUNL) for 810 MW solar power plant at Pugal Solar Park, Rajasthan

Read More
Sun Pharma’s MM-II Trial Shows Long-Lasting Relief for Knee Osteoarthritis
26 Apr 2025|01:15 PM

Based on the Phase 2b clinical trial, the study used a randomised, double-blind, placebo-controlled design that yielded strong and dependable data.

Read More
Sun Pharma to Acquire Nasdaq-Listed Checkpoint Therapeutics for $355 Million
10 Mar 2025|10:46 AM

The deal is expected to be completed in the second quarter of 2025, subject to customary closing conditions and regulatory approvals.

Read More
Sun Pharma Q3 Profit Jumps 19% YoY, Declares ₹10.50 Dividend
31 Jan 2025|10:17 PM

An interim dividend of ₹10.50 on the face value per share for FY25 has been declared.

Read More
Sun Pharma reports Q2 net profit at ₹3,040 Crore
29 Oct 2024|10:30 AM

Sun Pharma has bolstered its speciality pipeline with a partnership with Philogen to commercialise late-stage candidate Fibromun.

Read More
Sun Pharma's Hair Loss Drug Approved by USFDA
26 Jul 2024|01:45 PM

The US Food and Drug Administration (USFDA) has approved LEQSELVI (deuruxolitinib) 8 mg tablets, according to a regulatory filing.

Read More
Mayne Pharma Sues Sun Pharma in Patent Dispute
25 Jul 2024|11:57 AM

IMVEXXY is a vaginal insert designed to lessen pain during sexual activity after menopause which is manufactured by Mayne Pharma.

Read More
USFDA grills Sun Pharma for manufacturing issues at Dadra facility
4 Jul 2024|11:24 AM

The warning letter detailed substantial violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals at the facility.

Read More

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Knowledge Center
Logo

Logo IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000

Logo IIFL Capital Services Support WhatsApp Number
+91 9892691696

Download The App Now

appapp
Loading...

Follow us on

facebooktwitterrssyoutubeinstagramlinkedintelegram

2025, IIFL Capital Services Ltd. All Rights Reserved

ATTENTION INVESTORS

RISK DISCLOSURE ON DERIVATIVES

Copyright © IIFL Capital Services Limited (Formerly known as IIFL Securities Ltd). All rights Reserved.

IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)

ISO certification icon
We are ISO 27001:2013 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.